Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective.

High-throughput screening (HTS) represents a major cornerstone of drug discovery. The availability of an innovative, relevant and high-quality compound collection to be screened often dictates the final fate of a drug discovery campaign. Given that the chemical space to be sampled in research programs is practically infinite and sparsely populated, significant efforts and resources need to be invested in the generation and maintenance of a competitive compound collection. The European Lead Factory (ELF) project is addressing this challenge by leveraging the diverse experience and know-how of academic groups and small and medium enterprises (SMEs) engaged in synthetic and/or medicinal chemistry. Here, we describe the novelty, diversity, structural complexity, physicochemical characteristics and overall attractiveness of this first batch of ELF compounds for HTS purposes.

[1]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[2]  Adam Nelson,et al.  Exploitation of the Ugi–Joullié Reaction in the Synthesis of Libraries of Drug-Like Bicyclic Hydantoins , 2015 .

[3]  Fabrizio Giordanetto,et al.  Branching cascades provide access to two amino-oxazoline compound libraries. , 2015, Bioorganic & medicinal chemistry.

[4]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[5]  Adam Nelson,et al.  A systematic approach to diverse, lead-like scaffolds from α,α-disubstituted amino acids. , 2015, Chemical communications.

[6]  Nathan Brown,et al.  Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules , 2012, J. Chem. Inf. Model..

[7]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[8]  Jorge Sanchez-Quesada,et al.  Design and synthesis of 1,1-disubstituted-1-silacycloalkane-based compound libraries. , 2015, Bioorganic & medicinal chemistry.

[9]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[10]  Stuart L. Schreiber,et al.  Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections , 2011, Proceedings of the National Academy of Sciences.

[11]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[12]  Adam Nelson,et al.  Aminomethylhydroxylation of alkenes: Exploitation in the synthesis of scaffolds for small molecule libraries. , 2015, Bioorganic & medicinal chemistry.

[13]  C. Wiesmann,et al.  The discovery of first-in-class drugs: origins and evolution , 2014, Nature Reviews Drug Discovery.

[14]  William Lewis,et al.  Combining two-directional synthesis and tandem reactions. Part 21: Exploitation of a dimeric macrocycle for chain terminus differentiation and synthesis of an sp(3)-rich library. , 2015, Bioorganic & medicinal chemistry.

[15]  Asher Mullard,et al.  European Lead Factory opens for business , 2013, Nature Reviews Drug Discovery.

[16]  C. Moody,et al.  Seven-membered ring scaffolds for drug discovery: Access to functionalised azepanes and oxepanes through diazocarbonyl chemistry. , 2015, Bioorganic & medicinal chemistry.

[17]  Herbert Waldmann,et al.  Stereoselective synthesis of a natural product inspired tetrahydroindolo[2,3-a]-quinolizine compound library. , 2015, Bioorganic & medicinal chemistry.

[18]  Alexander Dömling,et al.  Efficient isocyanide-less isocyanide-based multicomponent reactions. , 2015, Organic letters.

[19]  Mario van der Stelt,et al.  Cyclopentitol as a scaffold for a natural product-like compound library for drug discovery. , 2015, Bioorganic & medicinal chemistry.

[20]  Michael Williams,et al.  Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences? , 2011, Journal of Pharmacology and Experimental Therapeutics.

[21]  S. Langston,et al.  The Discovery of First-in-Class Inhibitors of the Nedd8-Activating Enzyme (NAE) and the Ubiquitin-Activating Enzyme (UAE) , 2017 .

[22]  Wolfgang H. B. Sauer,et al.  Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..

[23]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[24]  B. Munos,et al.  Can Open‐Source Drug R&D Repower Pharmaceutical Innovation? , 2010, Clinical pharmacology and therapeutics.

[25]  Alice McCarthy.  The NIH Molecular Libraries Program: identifying chemical probes for new medicines. , 2010, Chemistry & biology.

[26]  I. Khanna,et al.  Drug discovery in pharmaceutical industry: productivity challenges and trends. , 2012, Drug discovery today.

[27]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[28]  Thomas E Nielsen,et al.  Synthesis of hexahydropyrrolo[2,1-a]isoquinoline compound libraries through a Pictet-Spengler cyclization/metal-catalyzed cross coupling/amidation sequence. , 2015, Bioorganic & medicinal chemistry.

[29]  John G. Moffat,et al.  Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.

[30]  Markus Kaiser,et al.  Synthesis of a hexahydropyrrolo indole (HPI) compound library. , 2015, Bioorganic & medicinal chemistry.

[31]  A. H. Lipkus,et al.  Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .

[32]  Adam Nelson,et al.  A unified lead-oriented synthesis of over fifty molecular scaffolds. , 2015, Organic & biomolecular chemistry.

[33]  Thomas E Nielsen,et al.  Synthesis of 1,4,5 trisubstituted γ-lactams via a 3-component cascade reaction. , 2015, Bioorganic & medicinal chemistry.

[34]  Eberhardt Herdtweck,et al.  Leuckart-Wallach Route Toward Isocyanides and Some Applications. , 2015, ACS combinatorial science.

[35]  Mark J Wigglesworth,et al.  Increasing the delivery of next generation therapeutics from high throughput screening libraries. , 2015, Current opinion in chemical biology.

[36]  Fabrizio Giordanetto,et al.  Potential strategies for increasing drug-discovery productivity. , 2014, Future medicinal chemistry.

[37]  Adam Nelson,et al.  Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraries. , 2015, Bioorganic & medicinal chemistry.

[38]  Andrew L Hopkins,et al.  The Joint European Compound Library: boosting precompetitive research. , 2015, Drug discovery today.

[39]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[40]  Eberhardt Herdtweck,et al.  MCR synthesis of a tetracyclic tetrazole scaffold. , 2015, Bioorganic & medicinal chemistry.

[41]  F. Rutjes,et al.  Synthesis and functionalization of bicyclic N,O-acetal scaffolds from furfural. , 2015, Bioorganic & Medicinal Chemistry.

[42]  Asher Mullard.  2014 FDA drug approvals , 2015, Nature Reviews Drug Discovery.

[43]  A. Harvey,et al.  The re-emergence of natural products for drug discovery in the genomics era , 2015, Nature Reviews Drug Discovery.